Reading BAX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BAX free→Reading BAX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BAX free→QuarterlyIQ Insights · BAX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
The filing describes changes to the executive severance and change in control plan, which is a routine administrative matter.
of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
Other Events. Effective April 29, 2026, the Company's Board of Directors declared a quarterly cash dividend of $0.01 per share of common stock. The dividend is payable on July 1, 2026, to stockholders of record as of May 29, 2026.
CFO — Joel Grade: Joel Grade ceased his service as CFO and transitioned into a non-executive officer role.
Director — Cathy R. Smith, Stephen H. Rusckowski: Two directors resigned from the Board.
Other Events Effective February 11, 2026, the Company's Board of Directors declared a quarterly cash dividend of $0.01 per share of common stock. The dividend is payable on April 1, 2026, to stockholders of record as of February 27, 2026.
of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
Other Events. Final Results of Tender Offers On December 22, 2025 (the “Final Settlement Date”), Baxter International Inc. (the “Company”) effected the final settlement of the Company’s previously announced cash tender offers (each, a “Tender Offer” and together, the “Tender Offers”) to purchase (i) any and all of its 2.600% senior unsecured notes due 2026 (the “2026 Notes”) and (ii) a portion of its 1.915% senior unsecured notes due 2027 in an aggregate purchase price up to $600 million (the…
Termination of a Material Definitive Agreement. On December 4, 2025, the Company repaid all of its outstanding obligations under the Term Loan Credit Agreement using a portion of the net proceeds from the Notes.
below) ((i)-(iv), together with the offering of the Notes, the “Refinancing Transactions”). The Company intends to use any remaining net proceeds for general corporate purposes, including the payment of any fees and expenses in connection with the Refinancing Transactions and the November 25, 2025 amendment to its amended and restated five-year credit agreement dated June 11, 2025 and the repayment of the Company’s other indebtedness. Interest Rate and Maturity Interest on the 2029 Notes will…
Entry into a Material Definitive Agreement. Notes Offerings General On December 4, 2025, Baxter International Inc. (the “Company”) entered into the First Supplemental Indenture (the “Supplemental Indenture”) with U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), which supplements the Indenture, dated July 29, 2021 (the “Base Indenture” and together with the Supplemental Indenture, the “Indenture”), between the Company and the Trustee, relating to the issuance by the C…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information included in
Entry into a Material Definitive Agreement. On November 25, 2025, Baxter International Inc. (“ Baxter ”) entered into an amendment (“ Amendment No. 1 ”) to the amended and restated five-year credit agreement dated June 11, 2025, among Baxter, as Borrower Representative, Baxter Healthcare SA and Baxter World Trade SRL, as Borrowers, various lenders and JPMorgan Chase Bank, N.A., as Administrative Agent (as amended by Amendment No. 1, the “ Amended Credit Agreement ”). The purpose of Amendment…
Executive Vice President and Group President, Pharmaceuticals — Alok Sonig: Alok Sonig resigned to join another healthcare company.
of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
Executive Vice President, Chief Operating Officer (COO) and interim group president of Medical Products and Therapies (MPT) — Heather Knight: Heather Knight resigned to join another healthcare company.
of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
President and Chief Executive Officer — Andrew Hider: Appointment of Andrew Hider as President and CEO with Brent Shafer transitioning to Non-Executive Chair.
Entry into a Material Definitive Agreement. U.S. $2,200,000,000 Amended and Restated Five-Year Credit Agreement On June 11, 2025, Baxter International Inc. (“ Baxter ”) entered into an amended and restated five-year credit agreement (the “ RCF Amendment ”), which amends and restates in its entirety the existing $2.0 billion revolving credit agreement, dated as of September 30, 2021 (the “ Existing Revolving Credit Agreement ” and, as amended by the RCF Amendment, the “ Revolving Credit Agreem…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure provided under “Credit Agreements” in
Termination of a Material Definitive Agreement The disclosure provided under “Credit Agreements” in
of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Transition of José Almeida as CEO and Chair; Appointment of Brent Shafer as Interim CEO and Chair On February 3, 2025, the Company announced that, effective as of February 3, 2025 (the “CEO Transition Date”), José E. Almeida’s service as Chief Executive Officer (“CEO”) of the Company, Chair of the Board of Directors (the “Board”) and director has c…
and Item 7.01, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except in the event that the Company expressly states that such information is…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.